List of Excipients in Branded Drug VOQUEZNA DUAL PAK

« Back to Dashboard

Voquezna Dual Pak Excipient Strategy and Commercial Opportunities

Last updated: September 29, 2026

Voquezna Dual Pak combines vonoprazan fumarate tablets with amoxicillin capsules for 14-day eradication of Helicobacter pylori in adults. Its commercial value comes from acid suppression, simplified co-packaging, and avoidance of clarithromycin resistance rather than from a novel fixed-dose dosage form. The strongest excipient opportunities are dose uniformity, moisture protection, capsule-tablet compatibility, packaging-based adherence, and differentiated patient-use systems.

What is Voquezna Dual Pak and how is it administered?

Voquezna Dual Pak is a co-packaged H. pylori treatment containing:

Component	Strength	Administration
Vonoprazan fumarate tablet	20 mg	Twice daily
Amoxicillin capsule	500 mg each	Two capsules twice daily
Treatment duration	14 days	Four daily dosing events

The regimen delivers vonoprazan 20 mg twice daily and amoxicillin 1,000 mg twice daily. The product is approved for eradication of H. pylori infection in adults. Patients take the components together, generally without dependence on meal timing. The absence of clarithromycin distinguishes Dual Pak from Voquezna Triple Pak and positions it for use where macrolide resistance or prior macrolide exposure reduces the attractiveness of clarithromycin-containing therapy (U.S. Food and Drug Administration [FDA], 2023a).

Voquezna Dual Pak is not a conventional fixed-dose combination tablet. It is a synchronized package containing separate dosage forms. That structure preserves the established manufacturing and regulatory identity of each active ingredient while allowing the sponsor to market one treatment course.

What excipients are used in Voquezna Dual Pak?

The vonoprazan tablet uses a conventional immediate-release solid oral formulation architecture. Product-label information identifies excipients including mannitol, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, and film-coating materials such as hypromellose, titanium dioxide, talc, and colorants, depending on the specific presentation and labeling description (FDA, 2023a).

The amoxicillin capsule is a conventional hard-gelatin capsule dosage form. Its excipient system generally includes capsule-shell gelatin and opacifying or coloring agents, with formulation-specific materials used in the filled powder or granule blend. The exact excipient profile should be evaluated at the marketed National Drug Code and manufacturing-site level because co-packaged products can contain a branded active component and a separately manufactured antibiotic component.

Functional role of the principal excipients

Excipient class	Likely function in the vonoprazan tablet	Commercial relevance
Mannitol	Diluent and mouthfeel modifier	Supports compactability and tablet size control
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup
Hydroxypropyl cellulose	Binder	Supports granulation and mechanical strength
Magnesium stearate	Lubricant	Controls ejection and manufacturing friction
Hypromellose	Film former	Protects the tablet and supports identification
Titanium dioxide and iron oxides	Opacifier and colorant	Supports product differentiation and light protection
Talc	Coating aid	Improves film-coating processability

For the amoxicillin capsule, the primary excipient priorities are powder flow, fill-weight control, moisture management, capsule-shell integrity, and stability of the beta-lactam antibiotic.

How does excipient strategy affect Voquezna Dual Pak stability?

Vonoprazan and amoxicillin impose different formulation constraints. Vonoprazan is a potassium-competitive acid blocker formulated as a solid oral tablet. Amoxicillin is a beta-lactam antibiotic with sensitivity to moisture, heat, and formulation conditions that can accelerate degradation.

The co-pack therefore requires compatibility at the package level rather than chemical compatibility inside a single dosage form. The principal stability risks are:

1. Moisture transfer between components.
2. Loss of amoxicillin potency during the 14-day course.
3. Tablet friability or coating damage during shipment.
4. Capsule-shell brittleness or softening.
5. Cross-contamination of tablets and capsules during packaging.
6. Confusion caused by multiple dosage forms and repeated daily dosing.

A moisture-barrier blister or high-barrier bottle system can reduce exposure to humidity. Desiccants may be useful in bottle configurations, but they introduce ingestion, child-safety, and packaging-complexity considerations. Unit-dose blisters provide stronger dose organization and can reduce the number of patient handling events.

The most commercially valuable excipient and packaging work is likely to occur at the interface between stability and adherence. A formulation that extends shelf life by a limited amount has less market impact than a package that reduces missed doses across a 14-day regimen.

What formulation patents protect Voquezna Dual Pak?

The principal intellectual-property value is likely divided among several layers:

Protection layer	Potential subject matter	Strategic value
Vonoprazan composition patents	Active compound, salts, crystalline forms	Protects the acid-suppression component
Vonoprazan formulation patents	Tablet composition, release profile, stability	Can restrict alternative tablet formulations
H. pylori method patents	Use of vonoprazan with amoxicillin	Supports indication-specific exclusivity
Co-packaging patents	Coordinated packaging of vonoprazan and amoxicillin	Protects treatment-course presentation
Manufacturing patents	Crystallization, granulation, coating, or packaging processes	Can raise development costs for competitors
Trademark and trade-dress rights	Voquezna and package presentation	Supports commercial differentiation

The core commercial protection does not necessarily require a patent on every excipient. A sponsor can preserve market differentiation through the combination of active-ingredient rights, method-of-use claims, product-by-process claims, packaging claims, and regulatory exclusivity.

A definitive Orange Book patent assessment requires the current FDA listing for the relevant Voquezna presentation and patent status. The key diligence issue is whether listed patents cover vonoprazan itself, the specific H. pylori regimen, the co-pack, or only narrower formulation and use claims. A generic applicant could challenge one layer while designing around another.

What is the Orange Book status and FDA regulatory position of Voquezna Dual Pak?

Voquezna Dual Pak received FDA approval in November 2023 as part of Phathom Pharmaceuticals’ H. pylori treatment portfolio. The approval followed earlier FDA approval of Voquezna for erosive esophagitis and non-erosive gastroesophageal reflux disease, creating a broader development and commercial platform for vonoprazan (FDA, 2023a; Phathom Pharmaceuticals, 2023).

Regulatory characteristics include:

• New drug application pathway for the vonoprazan-containing product.
• Adult H. pylori indication.
• Separate tablet and capsule dosage forms within one commercial pack.
• Treatment-course packaging rather than a single fixed-dose tablet.
• No biosimilar pathway because vonoprazan and amoxicillin are small-molecule drugs.
• Generic substitution risk for the individual amoxicillin component, subject to the co-pack structure and state substitution rules.

Dual Pak and Triple Pak are small-molecule products. Biosimilar risk is therefore not relevant. The relevant competitive threats are generic vonoprazan, generic amoxicillin, alternative potassium-competitive acid blockers, and non-clarithromycin H. pylori regimens.

When does Voquezna Dual Pak lose exclusivity?

Voquezna Dual Pak can lose commercial exclusivity in stages rather than on one date.

Regulatory exclusivity

The 2023 approval may provide five years of new chemical entity exclusivity for vonoprazan if the FDA determines that the active moiety qualifies and no statutory exception applies. Because vonoprazan had prior U.S. approvals for other indications, the exact exclusivity analysis depends on the FDA’s regulatory classification and the specific NDA supplement or original NDA associated with the product.

A three-year approval-related exclusivity period may apply to certain new clinical investigations supporting an indication or formulation, but such protection is generally narrower than new chemical entity exclusivity and may not block all generic development.

Patent exclusivity

Patent expiration depends on the claims and patent-term adjustments. The principal expiration date for the marketed regimen may differ from expiration dates for:

• Vonoprazan active-ingredient patents.
• Vonoprazan salt or crystalline-form patents.
• Tablet formulation patents.
• H. pylori method-of-use patents.
• Co-packaging patents.
• Pediatric or supplemental indication patents.

The relevant launch risk is therefore a claim-by-claim assessment. A generic applicant may pursue a Paragraph IV certification against listed patents while accepting that other patents remain in force.

Which companies are challenging Voquezna Dual Pak?

The current public record does not establish a major publicly disclosed Paragraph IV litigation campaign specifically directed at Voquezna Dual Pak. The competitive field is more likely to develop through generic-drug filings and alternative regimen adoption than through biosimilar entry.

Potential challengers include:

• Generic manufacturers seeking approval for vonoprazan tablets.
• Manufacturers offering amoxicillin capsules in a coordinated co-pack.
• Companies developing alternative vonoprazan-amoxicillin presentations.
• Developers of other potassium-competitive acid blockers.
• Suppliers of optimized H. pylori regimens using rifabutin, tetracycline, metronidazole, or bismuth.

A generic applicant could take several approaches:

1. File for vonoprazan alone and compete with the branded acid-suppression component.
2. Market amoxicillin separately and rely on physician or pharmacy assembly.
3. Develop a dual co-pack with different packaging and excipient systems.
4. Challenge method-of-use claims while avoiding formulation claims.
5. Wait for key compound patents to expire and enter with a narrow label.

The most difficult generic product would be an exact commercial substitute for the branded 14-day package. The simplest entry would be generic vonoprazan sold separately, with amoxicillin obtained through ordinary pharmacy dispensing.

What excipient opportunities exist for suppliers?

Excipient suppliers can target the product’s operational problems rather than merely replace existing ingredients.

Moisture-control systems

Amoxicillin stability creates demand for:

• Low-moisture capsule excipients.
• Moisture-barrier films.
• High-barrier blister laminates.
• Desiccant-integrated packaging.
• Low-water-activity granulation systems.

A supplier that can demonstrate equivalent or improved stability without increasing tablet size or manufacturing complexity has a direct value proposition.

Direct-compression platforms

A direct-compression vonoprazan tablet could reduce processing steps and improve manufacturing flexibility. Candidate platforms include co-processed mannitol-cellulose systems, spray-dried fillers, and low-dose-content uniformity technologies.

The challenge is balancing:

• Low active loading.
• Uniform distribution.
• Rapid disintegration.
• Adequate hardness.
• Low friability.
• Robust tablet ejection.

Taste and swallowability improvements

Patients take several capsules and tablets each day for two weeks. Smaller tablets, improved film coating, reduced capsule size, and smoother capsule shells can support adherence. Taste masking is less important for intact adult dosage forms than swallowability and dosage-form recognition, but it can matter if future products target patients with dysphagia or enteral administration.

Color and identification systems

Distinct tablet and capsule colors can reduce dosing errors. The package should make the twice-daily regimen visually obvious without creating confusion between the two active ingredients. Colorants and film coatings can be part of a broader medication-use design, particularly in unit-dose blister cards.

What commercial opportunities exist beyond the current Dual Pak?

The most credible opportunities are packaging, line extensions, and institutional distribution.

Pediatric and dysphagia-oriented presentations

The current adult regimen leaves potential demand for:

• Smaller tablets.
• Sprinkleable formulations.
• Oral granules.
• Oral suspensions.
• Dispersible dosage forms.
• Feeding-tube-compatible presentations.

These products would require new formulation, palatability, stability, and dosing studies. Pediatric development could expand treatment access but would create a larger excipient and regulatory burden.

Hospital and public-health packaging

H. pylori treatment is vulnerable to incomplete adherence. Pharmacy-dispensed course packs, calendar blisters, and electronic adherence packaging could improve completion rates. Institutional buyers may value reduced pharmacist assembly, fewer dispensing errors, and lower treatment abandonment.

Global-market adaptation

Outside the United States, commercial opportunities depend on local H. pylori resistance patterns, pricing, and regulatory requirements. Packaging may need adaptation for:

• Humid climates.
• Heat exposure.
• Multilingual instructions.
• Different capsule color restrictions.
• Country-specific antibiotic labeling.
• Local prescription and reimbursement systems.

High-barrier packaging and extended in-use stability can be particularly important in markets with weak cold-chain infrastructure, although the product is an oral solid and does not generally require refrigerated distribution.

How does Voquezna Dual Pak compare with Voquezna Triple Pak?

Attribute	Voquezna Dual Pak	Voquezna Triple Pak
Acid suppression	Vonoprazan	Vonoprazan
Antibiotic backbone	Amoxicillin	Amoxicillin plus clarithromycin
Resistance positioning	Avoids clarithromycin	Exposed to clarithromycin resistance
Dosage-form complexity	Tablet plus capsules	Tablet plus capsules
Excipient challenge	Moisture and dose organization	Moisture, dose organization, and additional antibiotic stability
Commercial use case	Broad non-clarithromycin regimen	Select patients appropriate for clarithromycin
Biosimilar risk	None	None
Generic substitution complexity	Moderate	Higher because of three active components

Dual Pak has a simpler antimicrobial composition and a broader resistance-based commercial narrative. Triple Pak may remain relevant where clarithromycin susceptibility is known, but it has a narrower positioning in settings with high macrolide resistance or prior macrolide exposure.

What generic entry risks exist for Voquezna Dual Pak?

The highest-risk scenario is staged generic entry. A generic vonoprazan product could erode the branded acid-suppression component before a complete branded-style co-pack becomes available. Physicians and pharmacists could then assemble vonoprazan plus amoxicillin using separate prescriptions.

Other risks include:

• Low-cost amoxicillin substitution.
• Competing H. pylori regimens with established reimbursement.
• Insurer preference for separate generic components.
• Limited willingness to pay for a branded co-pack.
• Nonadherence if patients must assemble separate products.
• Patent settlements that permit an earlier generic launch.
• Formulation workarounds using different tablet excipients and packaging.

The co-pack’s defensibility is strongest when the sponsor demonstrates lower treatment friction, better completion rates, fewer dispensing errors, and favorable payer economics. Patent protection alone may not preserve the price premium if generic components are easy to obtain separately.

How strong is the patent estate for Voquezna Dual Pak?

The patent estate is strongest where several layers overlap: vonoprazan compound protection, formulation protection, H. pylori method claims, and packaging or regimen claims. It is weaker if commercial protection depends mainly on a narrow co-packaging claim that competitors can avoid by selling the components separately.

A practical strength assessment should score:

Factor	Strong position	Weak position
Compound claims	Broad, unexpired claims	Compound claims expired or narrow
Formulation claims	Cover essential tablet architecture	Easy excipient substitution
Method claims	Cover clinically relevant regimen	Limited to narrow patient subgroup
Packaging claims	Cover commercially necessary presentation	Easily avoided by separate dispensing
Regulatory exclusivity	Blocks or delays generic approval	Only narrow indication protection
Litigation record	Validated claims or favorable settlement	Unresolved validity or enforceability issues

Key Takeaways

• Voquezna Dual Pak is a 14-day co-pack of vonoprazan tablets and amoxicillin capsules for adult H. pylori eradication.
• Its excipient strategy is conventional but commercially important because tablet performance, amoxicillin stability, and packaging usability must work together.
• The largest formulation opportunities involve moisture control, direct compression, unit-dose packaging, smaller dosage forms, and adherence-oriented presentation.
• Voquezna Dual Pak has no biosimilar risk. Its principal threats are generic vonoprazan, separate-component substitution, competing H. pylori regimens, and Paragraph IV challenges.
• Patent strength depends on the combined coverage of vonoprazan, formulation, method of use, co-packaging, and manufacturing rights.
• Dual Pak has a broader resistance-related commercial position than Triple Pak because it avoids clarithromycin.
• The most defensible commercial opportunity is a complete treatment-course system that reduces dispensing and adherence problems, not merely an alternative excipient composition.

FAQs

Can Voquezna Dual Pak be reformulated as one fixed-dose tablet?

Technically, a fixed-dose tablet could combine vonoprazan and amoxicillin, but the development burden would be substantial. Dose size, chemical stability, release behavior, manufacturing segregation, and tablet size would need evaluation. The current separate-dosage-form approach avoids those compatibility and manufacturing risks.

Which excipient is most important for amoxicillin stability in Dual Pak?

Moisture control is the central issue. The most important commercial solution may be the combined use of low-moisture excipients, protective capsule materials, high-barrier packaging, and validated in-use stability rather than substitution of a single excipient.

Does generic amoxicillin automatically create a generic Voquezna Dual Pak?

No. Generic amoxicillin can be dispensed separately, but that does not automatically create an FDA-approved equivalent to the branded co-pack. A complete generic substitute would need to address the applicable approval pathway, labeling, packaging, patents, and regulatory requirements.

Could Voquezna Dual Pak support a pediatric formulation?

Potentially, but pediatric use would require appropriate clinical evidence and a child-acceptable dosage form. Granules, suspensions, dispersible tablets, and smaller unit doses would create new excipient, palatability, stability, and dosing requirements.

What is the most attractive licensing opportunity around Dual Pak?

The most attractive opportunities are likely high-barrier packaging, adherence-focused unit-dose systems, optimized vonoprazan tablet platforms, and pediatric or dysphagia-compatible presentations. These technologies can create value without requiring ownership of the active pharmaceutical ingredients.

References

1. Phathom Pharmaceuticals, Inc. (2023). Phathom Pharmaceuticals announces FDA approval of Voquezna Triple Pak and Voquezna Dual Pak for the treatment of Helicobacter pylori infection.
2. U.S. Food and Drug Administration. (2023a). Voquezna prescribing information.
3. U.S. Food and Drug Administration. (2023b). Drugs@FDA: FDA-approved drugs database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. American College of Gastroenterology. (2024). ACG clinical guideline: Treatment of Helicobacter pylori infection.